BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 8624289)

  • 1. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
    Takemura Y; Jackman AL
    Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase inhibitors.
    Danenberg PV; Malli H; Swenson S
    Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
    Hanlon MH; Ferone R
    Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
    Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
    Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
    Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity.
    Rutenber EE; Stroud RM
    Structure; 1996 Nov; 4(11):1317-24. PubMed ID: 8939755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
    Dolnick BJ; Lu K; Yin MB; Rustum YM
    Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
    Jackman AL; Boyle FT; Harrap KR
    Invest New Drugs; 1996; 14(3):305-16. PubMed ID: 8958186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumour agents.
    Bavetsias V; Jackman AL
    Curr Med Chem; 1998 Aug; 5(4):265-88. PubMed ID: 9668195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition.
    Stout TJ; Stroud RM
    Structure; 1996 Jan; 4(1):67-77. PubMed ID: 8805515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
    Erlichman C; Mitrovski B
    Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.